Copyright Reports & Markets. All rights reserved.

Global Tumor Necrosis Factor Inhibitors Drug Sales Market Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Global Tumor Necrosis Factor Inhibitors Drug Sales Market Report 2019

      1 Tumor Necrosis Factor Inhibitors Drug Market Overview

      • 1.1 Tumor Necrosis Factor Inhibitors DrugProduct Overview
      • 1.2 Tumor Necrosis Factor Inhibitors Drug Segment by Type
        • 1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Comparison by Types (2014-2025)
        • 1.2.2 Cimzia (Certolizumab Pegol)
        • 1.2.3 Enbrel (Etanercept)
        • 1.2.4 Humira ( Adalimumab)
        • 1.2.5 Otezla (Apremilast)
        • 1.2.6 Remicade (Infliximab)
        • 1.2.7 Simponi (Golimumab)
      • 1.3 Tumor Necrosis Factor Inhibitors Drug Segment by Application
        • 1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Comparison by Application (2014-2025)
        • 1.3.1 Clinic
        • 1.3.2 Hospital
        • 1.3.3 Others
      • 1.4 Tumor Necrosis Factor Inhibitors Drug Market by Region
        • 1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue Comparison by Region (2014-2025)
        • 1.4.2 United States Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
        • 1.4.3 Europe Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
        • 1.4.4 China Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
        • 1.4.5 Japan Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
        • 1.4.6 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
        • 1.4.7 India Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2014-2025)
      • 1.5 Global Tumor Necrosis Factor Inhibitors Drug Sales and Revenue (2014-2025)
        • 1.5.1 Global Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2014-2025)
        • 1.5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2014-2025)

      2 Tumor Necrosis Factor Inhibitors Drug by Company, Region, Type and Application

      • 2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Competition by Companies
        • 2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share of Key Companies (2014-2019)
        • 2.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2014-2019)
      • 2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales and Revenue by Region
        • 2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2014-2019)
        • 2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2014-2019)
      • 2.3 Global Tumor Necrosis Factor Inhibitors Drug Sales and Revenue by Type
        • 2.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2014-2019)
        • 2.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2014-2019)
      • 2.4 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application

      3 United States Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 3.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Revenue (2014-2019)
        • 3.1.1 United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 3.1.2 United States Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 3.1.3 United States Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 3.2 United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 3.3 United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 3.4 United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      4 Europe Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 4.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales and Value (2014-2019)
        • 4.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 4.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 4.1.3 Europe Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 4.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 4.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 4.4 Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      5 China Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 5.1 China Tumor Necrosis Factor Inhibitors Drug Sales and Revenue (2014-2019)
        • 5.1.1 China Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 5.1.2 China Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 5.1.3 China Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 5.2 China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 5.3 China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 5.4 China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      6 Japan Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 6.1 Japan Tumor Necrosis Factor Inhibitors Drug Sales and Value (2014-2019)
        • 6.1.1 Japan Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 6.1.2 Japan Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 6.1.3 Japan Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 6.2 Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 6.3 Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 6.4 Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      7 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 7.1 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales and Value (2014-2019)
        • 7.1.1 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 7.1.2 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 7.1.3 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 7.2 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 7.3 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 7.4 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      8 India Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price

      • 8.1 India Tumor Necrosis Factor Inhibitors Drug Sales and Value (2014-2019)
        • 8.1.1 India Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2014-2019)
        • 8.1.2 India Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2014-2019)
        • 8.1.3 India Tumor Necrosis Factor Inhibitors Drug Price Trend (2014-2019)
      • 8.2 India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company
      • 8.3 India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
      • 8.4 India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application

      9 Company Profiles and Key Figures in Tumor Necrosis Factor Inhibitors Drug Business

      • 9.1 Apogenix
        • 9.1.1 Apogenix Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.1.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.1.4 Main Business and Markets Served
      • 9.2 AryoGen Biopharma
        • 9.2.1 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.2.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.2.4 Main Business and Markets Served
      • 9.3 Bionovis
        • 9.3.1 Bionovis Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.3.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.3.4 Main Business and Markets Served
      • 9.4 CASI Pharmaceuticals
        • 9.4.1 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.4.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.4.4 Main Business and Markets Served
      • 9.5 Celltrion
        • 9.5.1 Celltrion Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.5.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.5.4 Main Business and Markets Served
      • 9.6 Celgene Corporation
        • 9.6.1 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.6.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.6.4 Main Business and Markets Served
      • 9.7 Delenex Therapeutics
        • 9.7.1 Delenex Therapeutics Production Sites and Area Served
        • 9.7.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.7.4 Main Business and Markets Served
      • 9.8 Dexa Medica
        • 9.8.1 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.8.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.8.4 Main Business and Markets Served
      • 9.9 EPIRUS Biopharmaceuticals
        • 9.9.1 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.9.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.9.4 Main Business and Markets Served
      • 9.10 Janssen Biotech
        • 9.10.1 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Production Sites and Area Served
        • 9.10.2 Tumor Necrosis Factor Inhibitors Drug Specification and Application
        • 9.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.10.4 Main Business and Markets Served
      • 9.11 GlaxoSmithKline
      • 9.12 HanAll Biopharma
      • 9.13 Intas Pharmaceuticals
      • 9.14 LEO Pharma
      • 9.15 LG Life Sciences
      • 9.16 MedImmune
      • 9.17 Momenta Pharmaceuticals
      • 9.18 Novartis
      • 9.19 PROBIOMED
      • 9.20 Reliance Life Sciences
      • 9.21 Sandoz
      • 9.22 Samsung Bioepis
      • 9.23 Sanofi-Aventis
      • 9.24 Shanghai CP Guojian Pharmaceutical
      • 9.25 Shanghai Pharmaceuticals
      • 9.26 Simcere Pharmaceutical
      • 9.27 Toyama Chemical
      • 9.28 Tsumura
      • 9.29 UCB
      • 9.30 Zydus Cadila

      10 Tumor Necrosis Factor Inhibitors Drug Maufacturing Cost Analysis

      • 10.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials Analysis
        • 10.1.1 Key Raw Materials
        • 10.1.2 Key Raw Materials Price Trend
        • 10.1.3 Key Suppliers of Raw Materials
      • 10.2 Proportion of Manufacturing Cost Structure
      • 10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
      • 10.4 Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis

      11 Marketing Channel, Distributors and Customers

      • 11.1 Marketing Channel
        • 11.1.1 Direct Marketing
        • 11.1.2 Indirect Marketing
      • 11.2 Tumor Necrosis Factor Inhibitors Drug Distributors List
      • 11.3 Tumor Necrosis Factor Inhibitors Drug Customers

      12 Market Dynamics

      • 12.1 Market Trends
      • 12.2 Opportunities
      • 12.3 Market Drivers
      • 12.4 Challenges
      • 12.5 Influence Factors

      13 Tumor Necrosis Factor Inhibitors Drug Market Forecast

      • 13.1 Global Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Price Forecast
        • 13.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Growth Forecast (2019-2025)
        • 13.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Forecast (2019-2025)
        • 13.1.3 Global Tumor Necrosis Factor Inhibitors Drug Price Trend Forecast (2019-2025)
      • 13.2 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Region
        • 13.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Growth Forecast by Region (2019-2025)
        • 13.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Forecast by Region (2019-2025)
        • 13.2.3 United States Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.4 Europe Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.5 China Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.6 Japan Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.7 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.8 India Tumor Necrosis Factor Inhibitors Drug Sales, Revenue Growth Forecast (2019-2025)
      • 13.3 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Type
        • 13.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2019-2025)
        • 13.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Type (2019-2025)
        • 13.3.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2019-2025)
      • 13.4 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Application

      14 Research Findings and Conclusion

        15 Methodology and Data Source

        • 15.1 Methodology/Research Approach
          • 15.1.1 Research Programs/Design
          • 15.1.2 Market Size Estimation
          • 15.1.3 Market Breakdown and Data Triangulation
        • 15.2 Data Source
          • 15.2.1 Secondary Sources
          • 15.2.2 Primary Sources
        • 15.3 Author List

        The global Tumor Necrosis Factor Inhibitors Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report studies the global Tumor Necrosis Factor Inhibitors Drug market status and forecast, categorizes the global Tumor Necrosis Factor Inhibitors Drug market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

        Major manufacturers covered in this report
        Apogenix
        AryoGen Biopharma
        Bionovis
        CASI Pharmaceuticals
        Celltrion
        Celgene Corporation
        Delenex Therapeutics
        Dexa Medica
        EPIRUS Biopharmaceuticals
        Janssen Biotech
        GlaxoSmithKline
        HanAll Biopharma
        Intas Pharmaceuticals
        LEO Pharma
        LG Life Sciences
        MedImmune
        Momenta Pharmaceuticals
        Novartis
        PROBIOMED
        Reliance Life Sciences
        Sandoz
        Samsung Bioepis
        Sanofi-Aventis
        Shanghai CP Guojian Pharmaceutical
        Shanghai Pharmaceuticals
        Simcere Pharmaceutical
        Toyama Chemical
        Tsumura
        UCB
        Zydus Cadila

        In view of regional level, this report covers
        United States
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Cimzia (Certolizumab Pegol)
        Enbrel (Etanercept)
        Humira ( Adalimumab)
        Otezla (Apremilast)
        Remicade (Infliximab)
        Simponi (Golimumab)

        Segment by Application
        Clinic
        Hospital
        Others

        Buy now